Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-03
2011-11-15
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S285000
Reexamination Certificate
active
08058284
ABSTRACT:
The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.
REFERENCES:
patent: 3847925 (1974-11-01), Beregi et al.
patent: 4542139 (1985-09-01), Hitzel et al.
patent: 4720450 (1988-01-01), Ellis
patent: 5475025 (1995-12-01), Tjoeng et al.
patent: 6160000 (2000-12-01), Adams et al.
patent: 6413724 (2002-07-01), Gordeev et al.
patent: 6689786 (2004-02-01), Scarborough et al.
patent: 6824790 (2004-11-01), Yatvin
patent: 6906063 (2005-06-01), Scarborough et al.
patent: 6951937 (2005-10-01), Kanter et al.
patent: 7022731 (2006-04-01), Scarborough et al.
patent: 7056926 (2006-06-01), Scarborough et al.
patent: 7358257 (2008-04-01), Scarborough et al.
patent: 2002/0025961 (2002-02-01), Scarbrough et al.
patent: 2002/0077486 (2002-06-01), Scarborough
patent: 2003/0162774 (2003-08-01), Scarbrough et al.
patent: 2004/0147576 (2004-07-01), Scarbrough et al.
patent: 2004/0242658 (2004-12-01), Reddy et al.
patent: 2005/0107357 (2005-05-01), Scarbrough et al.
patent: 2005/0228029 (2005-10-01), Scarbrough et al.
patent: 2009/0042916 (2009-02-01), Sharp et al.
patent: 2009/0048216 (2009-02-01), Gretler et al.
patent: 2009/0156620 (2009-06-01), Sharp et al.
patent: 845 042 (1952-07-01), None
patent: 1 257 550 (2005-11-01), None
patent: 1 412 364 (2006-09-01), None
patent: 08-081442 (1996-03-01), None
patent: 10-502630 (1998-03-01), None
patent: 10-195323 (1998-07-01), None
patent: 2000-204081 (2000-07-01), None
patent: 2003-522177 (2003-07-01), None
patent: WO 94/19341 (1994-09-01), None
patent: WO 94/21602 (1994-09-01), None
patent: WO 96/02508 (1996-02-01), None
patent: WO 99/36425 (1999-07-01), None
patent: WO 01/57037 (2001-08-01), None
patent: WO 03/011872 (2003-02-01), None
patent: WO 2007/056167 (2007-05-01), None
Fredholm, Bertil B., “Towards a revised nomenclature for P1 and P2 receptors,”TIPS, 1997, vol. 18, pp. 79-82.
Hechler, Beatrice, et al., “The P2Y Receptor Is Necessary for Adenosine 5′ -Diphosphate-Induced Platelet Aggregation,”Blood, 1998, vol. 92, No. 1, pp. 152-159.
Hollopeter, Gunther, et al., “Identification of the platelet ADP receptor targeted by antithrombotic drugs,”Nature, 2001, vol. 409, pp. 202-207.
Hunt, Cecilia, et al., “3-Substituted Thieno[2,3-b][1,4]thiazine-6-sulfonamides. A Novel Class of Topically Active Carbonic Anhydrase Inhibitors,”J. Med. Chem, 1994, vol. 37, pp. 240-247.
Jantzen, H.M, et al., “Evidence for Two Distinct G-Protein-coupled ADP Receptors Mediating Platelet Activation,”Thrombosis and Haemostasis, 1999, vol. 81, No. 1, pp. 111-117.
King, Brian F, et al., “Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors,”TIPS, 1998, vol. 19, pp. 506-514.
Kunapuli, Satya P., “Multiple P2 receptor subtypes on platelets: a new interpretation of their function,”TIPS, 1998, vol. 19, pp. 381-394.
Kunapuli, Satya P, et al., “P2 receptor subtypes in the cardiovascular system,”J. Biochem, 1998, vol. 336, pp. 513-523.
Mills, D.C.B, “ADP Receptors on Platelets,”Thrombosis and Haemostasis, 1996, vol. 76, No. 6, pp. 835-856.
Plotnikova, et al., “Arenesulfonamides, LXXX. Aroylarenesulfonamides,” Database CA Online Chemical Abstracts Service, Columbus, OH, US, retrieved from STN Database Accession No. 82 139564 XP002215531, abstract & Vopr. Khim, Khim. Tekhnol. (1974), vol. 33, pp. 20-25.
Hatzelmann, A., “Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005{(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid} and structurally related compounds,”Biochemical Pharmacology, 1993, vol. 45, No. 1, pp. 101-111.
Holland, G.F., “Preparation of Some Additional Sulfonylureas,”Journal of Organic Chemistry, May 1961, vol. 26, pp. 1662-1665.
Lacan, F., “Synthesis, structural characterization and thromboxane A2 receptor antagonistic activity of 3-substiuted 2-[(aryslulfonyl) imino]-2, 3-dihydrothiaozyl derivatives,”European Journal of Medicinal Chemistry, 1999, vol. 34, No. 4, pp. 311-328.
Supplementary European Search Report mailed on Apr. 29, 2009, for EP Application No. 06827506.4, 3 pages.
Stack, D., “Electron Withdrawing and Electron Donating Groups,” 2010, 2 pages.
Stack, D., “EWD-EDG Worksheet,” 2010, located at <http://myweb.unomaha.edu/˜dstack/2250/Problems/EWG—EDG.doc>, 4 pages.
Vippagunta, S.R. et al., “Crystalline solids,”Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
Cannon Hilary
Grant Craig M.
Huang Wolin
Mehrotra Mukund
Scarborough Robert
Bernhardt Emily
Kilpatrick Townsend and Stockton LLP
Portola Pharmaceuticals Inc.
LandOfFree
[4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286168